TristelTSNLF +6.35%96 Days Payable is 129.25 as of Dec. 2025, which is 27% above its 10-year median of 101.95. GuruFocus rates TSNLF with a GF Score™ of 96/100 and a GF Value™ of $6.94 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, Tristel ranks better than 76.35% on this metric.
Tristel's average Accounts Payable for the
six
months ended in Dec. 2025 was $4.62 Mil. Tristel's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $6.52 Mil.
Hence, Tristel's Days Payable for the
six
months ended in Dec. 2025 was 129.25.
The historical rank and industry rank for Tristel's Days Payable or its related term are showing as below:
TSNLF'
s Days Payable Range Over the Past 10 Years
Min: 43.83 Med: 101.95 Max: 165.55
Current: 141.88
During the past 13 years, Tristel's highest Days Payable was 165.55. The lowest was 43.83. And the median was 101.95.
TSNLF's Days Payable is ranked better than 76.35% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs TSNLF: 141.88
Tristel's Days Payable
declined
from Dec. 2024 (139.09) to Dec. 2025 (129.25).
It may suggest that Tristelaccelerated paying its suppliers.
Tristel Days Payable Related Terms
Tristel Days Payable Historical Data
* Premium members only.
The historical data trend for Tristel's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Tristel's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's Days Payable distribution charts can be found below:
* The bar in red indicates where Tristel's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tristel's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tristel (TSNLF) has a Days Payable of 129.25 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tristel and its competitors. This is 27% above median its historical median of 101.95. Over the past decade, Tristel's Days Payable has ranged from 43.83 to 165.55. According to the industry distribution chart, Tristel ranks #188 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 23.6%.
Is Tristel's Days Payable too high?
Tristel's current Days Payable of 129.25 is 27% above median its 10-year median of 101.95. Over the past 10 years, this metric has ranged from a low of 43.83 to a high of 165.55. The Medical Devices & Instruments industry median Days Payable is 68.07. Tristel's value of 129.25 is 89.9% above this industry median. Based on the distribution chart, Tristel ranks #188 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tristel has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tristel's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tristel ranks #188 out of 795 companies for Days Payable. This places Tristel in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Tristel's value of 129.25 is 89.9% above this benchmark. Historically, Tristel's own Days Payable has ranged from 43.83 to 165.55 over the past decade. While the company's 10-year median is 101.95 vs. the industry median of 68.07, Tristel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tristel's current Days Payable of 129.25 is 89.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tristel and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tristel's current Days Payable is 129.25, which is 27% above median its own 10-year median of 101.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.94, compared to a current price of $5.53 — trading 20.3% below its estimated fair value. The current Days Payable is 129.25, which is 27% above median its 10-year median of 101.95 and 89.9% above the Medical Devices & Instruments industry median of 68.07. Tristel's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tristel (TSNLF), the current Days Payable is 129.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.53 is trading 20.3% below its estimated GF Value™ of $6.94.
GuruFocus considers Tristel to be Modestly Undervalued.
Key valuation signals for TSNLF:
Days Payable: 129.25 (27% above median its 10-year median of 101.95)
GF Value™: $6.94 vs. price of $5.53 (20.3% below fair value)
Industry Position: 89.9% above the Medical Devices & Instruments median (#188 of 795)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
96GF Score
Get the complete analysis for TSNLF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
